{"gene":"GABPB2","run_date":"2026-04-28T17:46:04","timeline":{"discoveries":[{"year":1993,"finding":"GABP (GA-binding protein) was shown to be identical to NRF-2 (Nuclear Respiratory Factor 2), a multisubunit transcription factor that activates cytochrome c oxidase subunit IV and Vb gene promoters through tandem ETS recognition sites. The complex was purified from HeLa cells and found to consist of five polypeptides, with only one (the alpha subunit) having intrinsic DNA-binding ability; the beta subunits (including what is now GABPB2) participate in heteromeric complex formation with distinct binding properties.","method":"Protein purification from HeLa cells, peptide sequencing, gel retardation/EMSA, promoter activity assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — biochemical purification to homogeneity, peptide sequencing, functional promoter assays, replicated across multiple genes","pmids":["8383622"],"is_preprint":false},{"year":1993,"finding":"E4TF1-47 (a subunit equivalent to GABPB2) was cloned and shown to have no DNA binding activity but can associate with E4TF1-60 (GABPα). E4TF1-47 and E4TF1-53 share identical N-terminal sequences (332 aa) but differ at the C-terminus; all three recombinant subunits behaved identically to purified native proteins in gel retardation assays, and GABP-specific antibody recognized human E4TF1, confirming the identity.","method":"cDNA cloning, recombinant protein expression in E. coli, gel retardation assay, antibody recognition","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical reconstitution with recombinant proteins and functional assay validation","pmids":["8441384"],"is_preprint":false},{"year":1994,"finding":"The mouse genome encodes two highly related GABP beta polypeptides, GABP beta 1-1 and GABP beta 2-1 (encoded by Gabpb2). The molecular basis of GABP beta dimerization was resolved: carboxy-terminal regions of both GABP beta polypeptides mediate dimerization via coiled-coil alpha-helical structures. Evidence includes (1) the dimer-forming region of GABP beta 2-1 can functionally replace the leucine zipper of a bZIP transcription factor, and (2) a synthetic peptide corresponding to this region shows distinctive helical properties by circular dichroism spectroscopy. GABP beta 1-1 and GABP beta 2-1 can heterodimerize through this carboxy-terminal domain, but neither can heterodimerize via the bZIP protein C/EBP beta dimer-forming region.","method":"cDNA cloning, leucine zipper replacement functional assay, circular dichroism spectroscopy, co-immunoprecipitation/dimerization assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — functional domain swap, circular dichroism structural analysis, multiple orthogonal methods","pmids":["7958862"],"is_preprint":false},{"year":1995,"finding":"GABPB2 (NRF-2 beta 2) was shown to be one of four non-DNA-binding subunits of human NRF-2 that share a conserved transcriptional activation domain. Human-specific variants (beta 2 and gamma 2) differ from rodent GABP beta subunits by a 12-amino-acid insertion containing serine doublets. All four beta/gamma subunits associate equally with the alpha (DNA-binding) subunit, direct high-affinity binding of alpha to tandem RCO4 promoter sites, and are equally proficient in activating transcription when fused to a GAL4 DNA-binding domain. The transactivation domain was localized by deletion mapping to ~70 amino acids containing repeated glutamine-rich hydrophobic clusters.","method":"cDNA cloning, overexpression, co-immunoprecipitation, GAL4 fusion transactivation assay, deletion mapping","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — deletion mapping with functional readout, multiple subunit comparisons, GAL4 fusion assays","pmids":["7799916"],"is_preprint":false},{"year":1996,"finding":"The transcriptional activation domain of NRF-2 (which includes GABPB2 as a subunit) was characterized by deletion and alanine substitution mutagenesis, revealing that activation requires tandemly arranged clusters of hydrophobic amino acids (not glutamines, prolines, or isoleucines per se). The essential hydrophobic motifs within the NRF-2 activation domain are contained within ~40 residues, and the glutamine residues within those clusters are dispensable for activation.","method":"Deletion mutagenesis, alanine substitution mutagenesis, transactivation assays in transfected cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with functional readout, multiple substitution mutants tested","pmids":["8816484"],"is_preprint":false},{"year":1998,"finding":"Crystal structure of GABPα/β ETS domain–ankyrin repeat heterodimer bound to DNA was determined at 2.15 Å resolution. The structure shows that the alpha subunit's ETS domain and a C-terminal extension together recruit the beta subunit (which contains ankyrin repeats), revealing an extensive protein-protein interface. The ETS domain binds a core GGA DNA-recognition motif. The beta subunit (GABPB) uses its ankyrin repeats to interface with the alpha subunit.","method":"X-ray crystallography at 2.15 Å resolution","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure, foundational structural study","pmids":["9461436"],"is_preprint":false},{"year":2000,"finding":"The cellular coactivator C1/HCF directly interacts with GABP, and this interaction is required for GABP-mediated transcriptional activation of HSV-1 immediate early gene enhancers. Mutations reducing GABP transactivation potential also impair the C1-GABP interaction, demonstrating that C1/HCF functions as a novel coactivator of GABP. C1/HCF coordinates assembly of multiprotein enhancer complexes by interacting with Oct-1, alphaTIF, and GABP.","method":"Co-immunoprecipitation, transactivation assays, mutagenesis","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal co-IP with mutagenesis validation, but describes GABP complex generally (not GABPB2-specific isoform)","pmids":["10675337"],"is_preprint":false},{"year":2008,"finding":"PRC (PGC-1-related coactivator) does not directly bind NRF-2(GABP) but associates with it in a complex mediated by HCF-1. Both PRC and NRF-2 beta subunits (including GABPB2) bind HCF-1 in vitro, and determinants required for these interactions (a consensus HCF-1 binding site on PRC, and the NRF-2 activation domain) are also required for PRC trans-activation through promoter-bound NRF-2. PRC, NRF-2β, and HCF-1 all co-associate with NRF-2-dependent nuclear genes (TFB1M, TFB2M). shRNA knockdown of PRC reduces TFB2M mRNA, mitochondrial transcripts, and cytochrome oxidase activity.","method":"Co-immunoprecipitation, in vitro binding assay, ChIP, shRNA knockdown, cytochrome oxidase activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (co-IP, in vitro binding, ChIP, functional knockdown), strong mechanistic evidence","pmids":["18343819"],"is_preprint":false},{"year":2018,"finding":"GABPβ1L, a tetramer-forming isoform, is specifically required for TERT reactivation at mutant TERT promoters in glioblastoma. GABPB2 (the paralog) is functionally distinct: it cannot substitute for GABPβ1L in supporting TERT expression at mutant promoters under normal conditions, establishing GABPB2 and GABPβ1L as functionally non-redundant isoforms with respect to mutant TERT promoter-driven transcription.","method":"Genetic disruption (CRISPR), xenograft mouse model, telomere length analysis, cell viability assays","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic disruption with defined phenotype, in vivo validation, but GABPB2 role described indirectly as non-redundant paralog","pmids":["30205050"],"is_preprint":false},{"year":2021,"finding":"Upregulation of GABPB2 protein expression can rescue the proliferative dependence of TERT promoter mutant glioblastoma cells on GABPβ1L, demonstrating that GABPB2 is functionally capable of substituting for GABPβ1L when overexpressed. Under normal conditions GABPB2 is expressed at very low levels, but forced upregulation compensates for GABPβ1L loss.","method":"Inducible knockdown of GABPβ1L, GABPB2 overexpression rescue experiments, intracranial tumor models, temozolomide combination treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — genetic rescue experiment with in vivo validation, but single lab","pmids":["33758097"],"is_preprint":false},{"year":2014,"finding":"During osteogenic differentiation of human Saos-2 cells, GABPβ2 expression peaks at day 3 (coinciding with Runx2 peak) and then declines. Immunocytochemical staining showed that GABPβ2 is initially diffuse in the cytoplasm but on day 3 accumulates in both nuclei and cytoplasm before returning to predominantly nuclear localization by day 6, suggesting a regulated subcellular redistribution during early osteoblastic differentiation.","method":"Real-time PCR, immunocytochemical staining, alkaline phosphatase activity assay, mineralized nodule assessment","journal":"Folia histochemica et cytobiologica","confidence":"Low","confidence_rationale":"Tier 3 — single lab, descriptive localization without functional validation by loss-of-function","pmids":["25308738"],"is_preprint":false}],"current_model":"GABPB2 (GABPβ2/NRF-2β2) is a non-DNA-binding beta subunit of the heterotetrameric GABP/NRF-2 transcription factor complex that dimerizes via a C-terminal coiled-coil domain, associates with the DNA-binding GABPα subunit through ankyrin repeat interactions (as revealed by crystal structure), harbors a conserved ~70-aa hydrophobic transactivation domain, participates in a trimeric PRC–HCF-1–NRF-2β complex to regulate mitochondrial respiratory gene expression, and can functionally substitute for the GABPβ1L isoform in supporting TERT promoter-driven transcription in glioblastoma when overexpressed, though it is normally expressed at very low levels and is not the primary isoform recruited to mutant TERT promoters."},"narrative":{"teleology":[{"year":1993,"claim":"Establishing that GABP is identical to NRF-2 and consists of a single DNA-binding α subunit plus multiple non-DNA-binding β subunits (including what became GABPB2) resolved the subunit composition of a key transcription factor for mitochondrial respiratory gene promoters.","evidence":"Protein purification from HeLa cells with peptide sequencing, EMSA, and promoter activity assays; parallel cDNA cloning with recombinant reconstitution","pmids":["8383622","8441384"],"confidence":"High","gaps":["Structural basis of α–β interaction unknown at this stage","Functional differences between β subunit isoforms not addressed","Mechanism by which β subunits activate transcription unresolved"]},{"year":1994,"claim":"Demonstrating that GABPB2 dimerizes through a C-terminal coiled-coil domain — capable of functionally replacing a leucine zipper — established the molecular basis for GABP heterotetramer assembly and showed that β1 and β2 can heterodimerize.","evidence":"Leucine zipper domain-swap functional assay, circular dichroism spectroscopy, co-immunoprecipitation","pmids":["7958862"],"confidence":"High","gaps":["Whether β1/β2 heterodimerization versus homodimerization is preferred in vivo unknown","Physiological consequence of tetramerization on target gene selection not tested"]},{"year":1995,"claim":"Mapping a conserved ~70-amino-acid transactivation domain within all four human NRF-2 β/γ subunits, and showing equal association with α and equal transcriptional potency, demonstrated that GABPB2 carries autonomous activation capacity indistinguishable from other isoforms in vitro.","evidence":"GAL4 fusion transactivation assays with deletion mapping, co-immunoprecipitation","pmids":["7799916"],"confidence":"High","gaps":["Why multiple isoforms exist if activation potency is equivalent remained unexplained","In vivo isoform-specific promoter occupancy not examined"]},{"year":1996,"claim":"Fine mutagenesis of the activation domain showed that tandem hydrophobic clusters — not glutamine residues — are the essential determinants of transactivation, refining the molecular requirements for NRF-2β function.","evidence":"Systematic alanine substitution mutagenesis with reporter assays in transfected cells","pmids":["8816484"],"confidence":"High","gaps":["Identity of coactivators recruited by these hydrophobic motifs unknown at this point"]},{"year":1998,"claim":"The 2.15 Å crystal structure of the GABPα ETS domain–GABPβ ankyrin repeat heterodimer on DNA revealed the extensive protein–protein interface through which β subunits are recruited to α, establishing the structural framework for GABP complex assembly.","evidence":"X-ray crystallography at 2.15 Å resolution","pmids":["9461436"],"confidence":"High","gaps":["Structure captured β1 ankyrin repeats; whether GABPB2-specific insertions alter the interface was not resolved","No structure of the coiled-coil tetramerization domain"]},{"year":2000,"claim":"Identification of HCF-1 (C1) as a coactivator that directly contacts GABP and is required for GABP-dependent transcriptional activation linked the activation domain to a specific cofactor recruitment mechanism.","evidence":"Co-immunoprecipitation, mutagenesis correlated with loss of activation and HCF-1 binding","pmids":["10675337"],"confidence":"Medium","gaps":["Experiment addressed GABP complex generically; isoform-specific interaction with GABPB2 not distinguished","Whether HCF-1 interaction is relevant beyond HSV IE gene context unclear"]},{"year":2008,"claim":"Discovery that PRC, HCF-1, and NRF-2β form a trimeric complex on mitochondrial gene promoters — with HCF-1 bridging PRC to the NRF-2β activation domain — provided the mechanistic link between the coactivator cascade and mitochondrial respiratory chain gene expression.","evidence":"In vitro binding, co-immunoprecipitation, ChIP at TFB1M/TFB2M promoters, shRNA knockdown reducing cytochrome oxidase activity","pmids":["18343819"],"confidence":"High","gaps":["Relative contribution of GABPB2 versus GABPB1 to PRC–HCF-1 complex at endogenous loci not dissected","Whether the trimeric complex operates at all NRF-2 targets or a subset is unknown"]},{"year":2018,"claim":"Genetic disruption in glioblastoma established that GABPB1L — not GABPB2 — is specifically required for TERT reactivation at mutant TERT promoters, demonstrating functional non-redundancy between the two paralogs in a disease-relevant context.","evidence":"CRISPR disruption, xenograft tumor models, telomere length analysis","pmids":["30205050"],"confidence":"Medium","gaps":["Molecular basis of GABPB2's inability to substitute (e.g., expression level vs. intrinsic activity) not resolved","GABPB2 role defined negatively (cannot substitute) rather than by direct loss-of-function"]},{"year":2021,"claim":"Forced overexpression of GABPB2 rescued GABPB1L-dependent proliferation and TERT expression in glioblastoma, showing that GABPB2 is intrinsically competent but limited by low endogenous expression — clarifying that expression level, not biochemical activity, underlies paralog non-redundancy.","evidence":"Inducible knockdown of GABPB1L with GABPB2 overexpression rescue, intracranial tumor models","pmids":["33758097"],"confidence":"Medium","gaps":["Mechanism regulating GABPB2 low expression not identified","Single-lab finding not yet independently confirmed","Whether GABPB2 upregulation occurs naturally as a resistance mechanism in tumors unknown"]},{"year":null,"claim":"The physiological non-redundant functions of GABPB2 versus GABPB1 — beyond the TERT promoter context — remain undefined; no genome-wide target specificity, isoform-specific structural features, or regulatory mechanisms controlling GABPB2 expression have been characterized.","evidence":"","pmids":[],"confidence":"Low","gaps":["No ChIP-seq or CUT&RUN data distinguishing GABPB2-occupied versus GABPB1-occupied loci","No crystal structure of the GABPB2-specific C-terminal region or coiled-coil domain","Regulatory basis for low GABPB2 expression uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,4,7]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,7]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,4,7]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,7]}],"complexes":["GABP/NRF-2 heterotetramer","PRC–HCF-1–NRF-2β trimeric complex"],"partners":["GABPA","GABPB1","HCFC1","PPRC1"],"other_free_text":[]},"mechanistic_narrative":"GABPB2 (GA-binding protein subunit beta-2, also termed NRF-2β2) is a non-DNA-binding transcriptional coactivator subunit of the heterotetrameric GABP/NRF-2 complex, which activates nuclear genes encoding mitochondrial respiratory chain components and other targets bearing tandem ETS recognition sites [PMID:8383622, PMID:7799916]. GABPB2 associates with the DNA-binding GABPα subunit through N-terminal ankyrin repeats, as revealed by the 2.15 Å crystal structure of the α/β heterodimer on DNA, and homodimerizes or heterodimerizes with GABPB1 via a C-terminal coiled-coil domain [PMID:9461436, PMID:7958862]. Its transactivation domain, mapped to ~40–70 residues containing essential hydrophobic clusters, recruits the coactivator HCF-1, which in turn bridges PRC to NRF-2β to drive mitochondrial gene expression [PMID:8816484, PMID:18343819]. GABPB2 is normally expressed at low levels and is functionally non-redundant with the GABPB1L isoform at mutant TERT promoters in glioblastoma, though forced overexpression can compensate for GABPB1L loss [PMID:30205050, PMID:33758097]."},"prefetch_data":{"uniprot":{"accession":"Q8TAK5","full_name":"GA-binding protein subunit beta-2","aliases":[],"length_aa":448,"mass_kda":48.6,"function":"May function as transcription factor capable of interacting with purine rich repeats (GA repeats)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8TAK5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GABPB2","classification":"Not Classified","n_dependent_lines":89,"n_total_lines":1208,"dependency_fraction":0.07367549668874172},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GABPB2","total_profiled":1310},"omim":[{"mim_id":"621284","title":"GA-BINDING PROTEIN TRANSCRIPTION FACTOR, SUBUNIT BETA-2; GABPB2","url":"https://www.omim.org/entry/621284"},{"mim_id":"600610","title":"GA-BINDING PROTEIN TRANSCRIPTION FACTOR, SUBUNIT BETA-1; GABPB1","url":"https://www.omim.org/entry/600610"},{"mim_id":"600609","title":"GA-BINDING PROTEIN TRANSCRIPTION FACTOR, ALPHA SUBUNIT; GABPA","url":"https://www.omim.org/entry/600609"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GABPB2"},"hgnc":{"alias_symbol":["MGC29891"],"prev_symbol":[]},"alphafold":{"accession":"Q06547","domains":[{"cath_id":"1.25.40.20","chopping":"2-164","consensus_level":"high","plddt":94.5498,"start":2,"end":164}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06547","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q06547-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q06547-F1-predicted_aligned_error_v6.png","plddt_mean":68.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GABPB2","jax_strain_url":"https://www.jax.org/strain/search?query=GABPB2"},"sequence":{"accession":"Q06547","fasta_url":"https://rest.uniprot.org/uniprotkb/Q06547.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q06547/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06547"}},"corpus_meta":[{"pmid":"7958862","id":"PMC_7958862","title":"Molecular and genetic characterization of GABP beta.","date":"1994","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7958862","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25937073","id":"PMC_25937073","title":"Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer.","date":"2015","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25937073","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33758097","id":"PMC_33758097","title":"Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33758097","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28117656","id":"PMC_28117656","title":"Epigenetic profiling of human brain differential DNA methylation networks in schizophrenia.","date":"2016","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/28117656","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25308738","id":"PMC_25308738","title":"GABPβ2 expression during osteogenic differentiation from human osteoblast-like Saos-2 cells.","date":"2014","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/25308738","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34194624","id":"PMC_34194624","title":"TERT and its binding protein: overexpression of GABPA/B in high grade gliomas.","date":"2021","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/34194624","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39732885","id":"PMC_39732885","title":"Genome-wide analysis of alternative splicing differences in hepatic ischemia reperfusion injury.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39732885","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41173221","id":"PMC_41173221","title":"Study on the molecular mechanism of dietary FCE supplementation in regulating chicken meat quality.","date":"2025","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/41173221","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38444083","id":"PMC_38444083","title":"Integrated analysis of ceRNA-miRNA changes in paraquat-induced pulmonary epithelial-mesenchymal transition via high-throughput sequencing.","date":"2024","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38444083","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060904","id":"PMC_19060904","title":"An empirical framework for binary interactome mapping.","date":"2008","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/19060904","citation_count":652,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18976975","id":"PMC_18976975","title":"Genome-scale RNAi screen for host factors required for HIV replication.","date":"2008","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/18976975","citation_count":627,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16713569","id":"PMC_16713569","title":"A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16713569","citation_count":610,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9461436","id":"PMC_9461436","title":"The structure of GABPalpha/beta: an ETS domain- ankyrin repeat heterodimer bound to DNA.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9461436","citation_count":265,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8383622","id":"PMC_8383622","title":"Identity of GABP with NRF-2, a multisubunit activator of cytochrome oxidase expression, reveals a cellular role for an ETS domain activator of viral promoters.","date":"1993","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8383622","citation_count":262,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21516116","id":"PMC_21516116","title":"Next-generation sequencing to generate interactome datasets.","date":"2011","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/21516116","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31700067","id":"PMC_31700067","title":"LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31700067","citation_count":195,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18029348","id":"PMC_18029348","title":"Toward a confocal subcellular atlas of the human proteome.","date":"2007","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/18029348","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23684612","id":"PMC_23684612","title":"The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23684612","citation_count":112,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30205050","id":"PMC_30205050","title":"Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/30205050","citation_count":107,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7799916","id":"PMC_7799916","title":"Four structurally distinct, non-DNA-binding subunits of human nuclear respiratory factor 2 share a conserved transcriptional activation domain.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7799916","citation_count":100,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32694731","id":"PMC_32694731","title":"Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.","date":"2020","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694731","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8441384","id":"PMC_8441384","title":"cDNA cloning of transcription factor E4TF1 subunits with Ets and notch motifs.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8441384","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32814053","id":"PMC_32814053","title":"Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32814053","citation_count":79,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10675337","id":"PMC_10675337","title":"The novel coactivator C1 (HCF) coordinates multiprotein enhancer formation and mediates transcription activation by GABP.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10675337","citation_count":68,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18343819","id":"PMC_18343819","title":"PGC-1-related coactivator complexes with HCF-1 and NRF-2beta in mediating NRF-2(GABP)-dependent respiratory gene expression.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18343819","citation_count":66,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8816484","id":"PMC_8816484","title":"Nuclear respiratory factors 1 and 2 utilize similar glutamine-containing clusters of hydrophobic residues to activate transcription.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8816484","citation_count":66,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35831314","id":"PMC_35831314","title":"Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35831314","citation_count":65,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6200,"output_tokens":708,"usd":0.01461},"stage2":{"model":"claude-opus-4-6","input_tokens":3872,"output_tokens":1018,"usd":0.067215},"total_usd":0.292401,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":18209,"output_tokens":4349,"usd":0.059931},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":6906,"output_tokens":2636,"usd":0.150645}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"The mouse genome encodes two highly related GABP beta polypeptides, GABP beta 1-1 and GABP beta 2-1 (encoded by Gabpb2). The carboxy-terminal regions of both GABP beta polypeptides mediate dimerization via an alpha-helical coiled-coil mechanism: the dimer-forming region of GABP beta 2-1 can functionally replace the leucine zipper of a bZIP transcription factor, and a synthetic peptide from this region shows helical properties by circular dichroism spectroscopy. GABP beta 1-1 and GABP beta 2-1 can heterodimerize through this carboxy-terminal coiled-coil domain.\",\n      \"method\": \"cDNA/genomic cloning, leucine zipper functional replacement assay, circular dichroism spectroscopy, dimerization domain mutagenesis/characterization\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution and functional replacement assay plus biophysical validation (CD spectroscopy), foundational paper with 73 citations\",\n      \"pmids\": [\"7958862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GABPB2, normally expressed at very low levels, can rescue the proliferative dependence of TERT promoter mutant glioblastoma cells on GABPB1L. Up-regulation of GABPB2 compensates for GABPB1L knockdown, indicating that GABPB2 can functionally substitute for GABPB1L in the GABP transcription factor complex that activates the mutant TERT promoter.\",\n      \"method\": \"Inducible GABPB1L knockdown in glioblastoma cells with GABPB2 overexpression rescue experiment, in vitro and in vivo (intracranial) tumor models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD/OE with specific cellular phenotype and rescue, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"33758097\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GABPB2 is a constituent of the heterotetrameric GABP transcription factor complex that dimerizes through a carboxy-terminal coiled-coil domain and can heterodimerize with GABPB1; it normally exists at low levels but can functionally substitute for the GABPB1L isoform in activating the mutant TERT promoter in glioblastoma cells.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEPT papers.\n\n**Classification:**\n\n- [1] PMID:7958862 — KEEP (directly about GABPB2 molecular characterization)\n- [2] PMID:25937073 — EXCLUDE (expression/survival correlation, no mechanism)\n- [3] PMID:33758097 — KEEP (GABPB2 as functional paralog of GABPB1L in TERT regulation, mechanistic rescue experiment)\n- [4] PMID:28117656 — EXCLUDE (methylation correlation, no mechanism)\n- [5] PMID:25308738 — KEEP (GABPB2 expression/localization during osteogenic differentiation - has localization data)\n- [6] PMID:34194624 — EXCLUDE (expression correlation only)\n- [7] PMID:39732885 — EXCLUDE (AS expression study, no mechanism for GABPB2)\n- [8] PMID:41173221 — EXCLUDE (chicken meat quality, symbol collision context/no mechanism)\n- [9] PMID:38444083 — EXCLUDE (ceRNA expression study)\n\n**Gene2pubmed papers:**\n- PMID:16189514 — KEEP (interactome, GABPB2 detected as interactor)\n- PMID:12477932 — EXCLUDE (cDNA sequencing resource)\n- PMID:26186194 — KEEP (BioPlex interactome)\n- PMID:28514442 — KEEP (BioPlex 2.0)\n- PMID:26496610 — KEEP (quantitative interactome)\n- PMID:25416956 — KEEP (interactome map)\n- PMID:32296183 — KEEP (HuRI)\n- PMID:33961781 — KEEP (BioPlex 3.0)\n- PMID:22939629 — KEEP (protein complex census)\n- PMID:21873635 — EXCLUDE (GO annotation pipeline)\n- PMID:19060904 — EXCLUDE (methodology paper)\n- PMID:18976975 — EXCLUDE (HIV screen, GABPB2 not specifically studied)\n- PMID:16713569 — KEEP (ataxia interactome)\n- PMID:16344560 — EXCLUDE (alternative promoters survey)\n- PMID:26344197 — KEEP (metazoan complexes)\n- PMID:9461436 — KEEP (crystal structure of GABPα/β heterodimer - foundational)\n- PMID:8383622 — KEEP (NRF-2/GABP identity, cytochrome oxidase)\n- PMID:21516116 — EXCLUDE (methodology)\n- PMID:31700067 — EXCLUDE (case B: alt-locus product GABPB1-AS1 lncRNA, about GABPB1 not GABPB2)\n- PMID:18029348 — EXCLUDE (subcellular atlas, no GABPB2-specific mechanism)\n- PMID:23684612 — KEEP (GABP in Hippo pathway - but need to check if specific to GABPB2... describes GABP complex generally, relevant to subunit function)\n- PMID:30205050 — KEEP (GABPβ1L vs GABPB2 functional distinction in TERT regulation)\n- PMID:7799916 — KEEP (NRF-2 subunits including GABPB2 characterized)\n- PMID:32694731 — EXCLUDE (GABPB2 not specifically studied)\n- PMID:8441384 — KEEP (E4TF1/GABP subunit cloning, GABPB2 equivalent)\n- PMID:32814053 — EXCLUDE (ND interactome, GABPB2 not specifically studied)\n- PMID:10675337 — KEEP (HCF/C1 coactivator interaction with GABP)\n- PMID:18343819 — KEEP (PRC/HCF-1/NRF-2β complex - NRF-2β = GABPB2)\n- PMID:8816484 — KEEP (NRF-2 activation domain characterization)\n- PMID:35831314 — EXCLUDE (methodology)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"GABP (GA-binding protein) was shown to be identical to NRF-2 (Nuclear Respiratory Factor 2), a multisubunit transcription factor that activates cytochrome c oxidase subunit IV and Vb gene promoters through tandem ETS recognition sites. The complex was purified from HeLa cells and found to consist of five polypeptides, with only one (the alpha subunit) having intrinsic DNA-binding ability; the beta subunits (including what is now GABPB2) participate in heteromeric complex formation with distinct binding properties.\",\n      \"method\": \"Protein purification from HeLa cells, peptide sequencing, gel retardation/EMSA, promoter activity assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical purification to homogeneity, peptide sequencing, functional promoter assays, replicated across multiple genes\",\n      \"pmids\": [\"8383622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"E4TF1-47 (a subunit equivalent to GABPB2) was cloned and shown to have no DNA binding activity but can associate with E4TF1-60 (GABPα). E4TF1-47 and E4TF1-53 share identical N-terminal sequences (332 aa) but differ at the C-terminus; all three recombinant subunits behaved identically to purified native proteins in gel retardation assays, and GABP-specific antibody recognized human E4TF1, confirming the identity.\",\n      \"method\": \"cDNA cloning, recombinant protein expression in E. coli, gel retardation assay, antibody recognition\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical reconstitution with recombinant proteins and functional assay validation\",\n      \"pmids\": [\"8441384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The mouse genome encodes two highly related GABP beta polypeptides, GABP beta 1-1 and GABP beta 2-1 (encoded by Gabpb2). The molecular basis of GABP beta dimerization was resolved: carboxy-terminal regions of both GABP beta polypeptides mediate dimerization via coiled-coil alpha-helical structures. Evidence includes (1) the dimer-forming region of GABP beta 2-1 can functionally replace the leucine zipper of a bZIP transcription factor, and (2) a synthetic peptide corresponding to this region shows distinctive helical properties by circular dichroism spectroscopy. GABP beta 1-1 and GABP beta 2-1 can heterodimerize through this carboxy-terminal domain, but neither can heterodimerize via the bZIP protein C/EBP beta dimer-forming region.\",\n      \"method\": \"cDNA cloning, leucine zipper replacement functional assay, circular dichroism spectroscopy, co-immunoprecipitation/dimerization assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional domain swap, circular dichroism structural analysis, multiple orthogonal methods\",\n      \"pmids\": [\"7958862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GABPB2 (NRF-2 beta 2) was shown to be one of four non-DNA-binding subunits of human NRF-2 that share a conserved transcriptional activation domain. Human-specific variants (beta 2 and gamma 2) differ from rodent GABP beta subunits by a 12-amino-acid insertion containing serine doublets. All four beta/gamma subunits associate equally with the alpha (DNA-binding) subunit, direct high-affinity binding of alpha to tandem RCO4 promoter sites, and are equally proficient in activating transcription when fused to a GAL4 DNA-binding domain. The transactivation domain was localized by deletion mapping to ~70 amino acids containing repeated glutamine-rich hydrophobic clusters.\",\n      \"method\": \"cDNA cloning, overexpression, co-immunoprecipitation, GAL4 fusion transactivation assay, deletion mapping\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — deletion mapping with functional readout, multiple subunit comparisons, GAL4 fusion assays\",\n      \"pmids\": [\"7799916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The transcriptional activation domain of NRF-2 (which includes GABPB2 as a subunit) was characterized by deletion and alanine substitution mutagenesis, revealing that activation requires tandemly arranged clusters of hydrophobic amino acids (not glutamines, prolines, or isoleucines per se). The essential hydrophobic motifs within the NRF-2 activation domain are contained within ~40 residues, and the glutamine residues within those clusters are dispensable for activation.\",\n      \"method\": \"Deletion mutagenesis, alanine substitution mutagenesis, transactivation assays in transfected cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with functional readout, multiple substitution mutants tested\",\n      \"pmids\": [\"8816484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Crystal structure of GABPα/β ETS domain–ankyrin repeat heterodimer bound to DNA was determined at 2.15 Å resolution. The structure shows that the alpha subunit's ETS domain and a C-terminal extension together recruit the beta subunit (which contains ankyrin repeats), revealing an extensive protein-protein interface. The ETS domain binds a core GGA DNA-recognition motif. The beta subunit (GABPB) uses its ankyrin repeats to interface with the alpha subunit.\",\n      \"method\": \"X-ray crystallography at 2.15 Å resolution\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure, foundational structural study\",\n      \"pmids\": [\"9461436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The cellular coactivator C1/HCF directly interacts with GABP, and this interaction is required for GABP-mediated transcriptional activation of HSV-1 immediate early gene enhancers. Mutations reducing GABP transactivation potential also impair the C1-GABP interaction, demonstrating that C1/HCF functions as a novel coactivator of GABP. C1/HCF coordinates assembly of multiprotein enhancer complexes by interacting with Oct-1, alphaTIF, and GABP.\",\n      \"method\": \"Co-immunoprecipitation, transactivation assays, mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP with mutagenesis validation, but describes GABP complex generally (not GABPB2-specific isoform)\",\n      \"pmids\": [\"10675337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PRC (PGC-1-related coactivator) does not directly bind NRF-2(GABP) but associates with it in a complex mediated by HCF-1. Both PRC and NRF-2 beta subunits (including GABPB2) bind HCF-1 in vitro, and determinants required for these interactions (a consensus HCF-1 binding site on PRC, and the NRF-2 activation domain) are also required for PRC trans-activation through promoter-bound NRF-2. PRC, NRF-2β, and HCF-1 all co-associate with NRF-2-dependent nuclear genes (TFB1M, TFB2M). shRNA knockdown of PRC reduces TFB2M mRNA, mitochondrial transcripts, and cytochrome oxidase activity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, ChIP, shRNA knockdown, cytochrome oxidase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (co-IP, in vitro binding, ChIP, functional knockdown), strong mechanistic evidence\",\n      \"pmids\": [\"18343819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GABPβ1L, a tetramer-forming isoform, is specifically required for TERT reactivation at mutant TERT promoters in glioblastoma. GABPB2 (the paralog) is functionally distinct: it cannot substitute for GABPβ1L in supporting TERT expression at mutant promoters under normal conditions, establishing GABPB2 and GABPβ1L as functionally non-redundant isoforms with respect to mutant TERT promoter-driven transcription.\",\n      \"method\": \"Genetic disruption (CRISPR), xenograft mouse model, telomere length analysis, cell viability assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic disruption with defined phenotype, in vivo validation, but GABPB2 role described indirectly as non-redundant paralog\",\n      \"pmids\": [\"30205050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Upregulation of GABPB2 protein expression can rescue the proliferative dependence of TERT promoter mutant glioblastoma cells on GABPβ1L, demonstrating that GABPB2 is functionally capable of substituting for GABPβ1L when overexpressed. Under normal conditions GABPB2 is expressed at very low levels, but forced upregulation compensates for GABPβ1L loss.\",\n      \"method\": \"Inducible knockdown of GABPβ1L, GABPB2 overexpression rescue experiments, intracranial tumor models, temozolomide combination treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue experiment with in vivo validation, but single lab\",\n      \"pmids\": [\"33758097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"During osteogenic differentiation of human Saos-2 cells, GABPβ2 expression peaks at day 3 (coinciding with Runx2 peak) and then declines. Immunocytochemical staining showed that GABPβ2 is initially diffuse in the cytoplasm but on day 3 accumulates in both nuclei and cytoplasm before returning to predominantly nuclear localization by day 6, suggesting a regulated subcellular redistribution during early osteoblastic differentiation.\",\n      \"method\": \"Real-time PCR, immunocytochemical staining, alkaline phosphatase activity assay, mineralized nodule assessment\",\n      \"journal\": \"Folia histochemica et cytobiologica\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, descriptive localization without functional validation by loss-of-function\",\n      \"pmids\": [\"25308738\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GABPB2 (GABPβ2/NRF-2β2) is a non-DNA-binding beta subunit of the heterotetrameric GABP/NRF-2 transcription factor complex that dimerizes via a C-terminal coiled-coil domain, associates with the DNA-binding GABPα subunit through ankyrin repeat interactions (as revealed by crystal structure), harbors a conserved ~70-aa hydrophobic transactivation domain, participates in a trimeric PRC–HCF-1–NRF-2β complex to regulate mitochondrial respiratory gene expression, and can functionally substitute for the GABPβ1L isoform in supporting TERT promoter-driven transcription in glioblastoma when overexpressed, though it is normally expressed at very low levels and is not the primary isoform recruited to mutant TERT promoters.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GABPB2 encodes a beta subunit of the GA-binding protein (GABP) transcription factor complex that dimerizes through a carboxy-terminal alpha-helical coiled-coil domain and can heterodimerize with GABPB1 [PMID:7958862]. Although normally expressed at very low levels, GABPB2 can functionally substitute for GABPB1L in the heterotetrameric GABP complex to activate the mutant TERT promoter and sustain proliferation of TERT-promoter-mutant glioblastoma cells [PMID:33758097].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of GABPB2 as a second GABP beta subunit resolved how the GABP complex achieves heterotetrameric assembly: the carboxy-terminal coiled-coil of GABPB2 mediates dimerization and can heterodimerize with GABPB1, establishing the structural basis of GABP beta-beta partnerships.\",\n      \"evidence\": \"cDNA/genomic cloning, leucine zipper functional replacement assay, and circular dichroism spectroscopy in mouse\",\n      \"pmids\": [\"7958862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No crystal or cryo-EM structure of the GABPB2 coiled-coil dimer\",\n        \"Relative physiological roles of GABPB2 vs GABPB1 homodimers and heterodimers remain undefined\",\n        \"Endogenous target gene specificity of GABPB2-containing complexes not determined\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that GABPB2 overexpression rescues GABPB1L loss in TERT-promoter-mutant glioblastoma cells established that GABPB2 is a functionally redundant beta subunit capable of sustaining oncogenic TERT activation, explaining why its normally low expression may serve as a compensatory reservoir.\",\n      \"evidence\": \"Inducible GABPB1L knockdown with GABPB2 overexpression rescue in glioblastoma cell lines and intracranial tumor models\",\n      \"pmids\": [\"33758097\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Rescue shown only in the context of TERT-promoter-mutant glioblastoma; generalizability to other GABP-dependent contexts unknown\",\n        \"Endogenous upregulation mechanism of GABPB2 upon GABPB1L loss not characterized\",\n        \"Single-lab finding; independent replication in additional cancer models not yet reported\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The physiological function of GABPB2 in normal tissues and the full spectrum of transcriptional targets it regulates independently of GABPB1 remain uncharacterized.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No loss-of-function studies (knockout models) for GABPB2 in vivo\",\n        \"Genome-wide binding profiles (ChIP-seq) for GABPB2-containing complexes are lacking\",\n        \"No structural model of a GABPB2-containing GABP heterotetramer on DNA\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [\"GABP heterotetramer\"],\n    \"partners\": [\"GABPB1\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"GABPB2 (GA-binding protein subunit beta-2, also termed NRF-2β2) is a non-DNA-binding transcriptional coactivator subunit of the heterotetrameric GABP/NRF-2 complex, which activates nuclear genes encoding mitochondrial respiratory chain components and other targets bearing tandem ETS recognition sites [PMID:8383622, PMID:7799916]. GABPB2 associates with the DNA-binding GABPα subunit through N-terminal ankyrin repeats, as revealed by the 2.15 Å crystal structure of the α/β heterodimer on DNA, and homodimerizes or heterodimerizes with GABPB1 via a C-terminal coiled-coil domain [PMID:9461436, PMID:7958862]. Its transactivation domain, mapped to ~40–70 residues containing essential hydrophobic clusters, recruits the coactivator HCF-1, which in turn bridges PRC to NRF-2β to drive mitochondrial gene expression [PMID:8816484, PMID:18343819]. GABPB2 is normally expressed at low levels and is functionally non-redundant with the GABPB1L isoform at mutant TERT promoters in glioblastoma, though forced overexpression can compensate for GABPB1L loss [PMID:30205050, PMID:33758097].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing that GABP is identical to NRF-2 and consists of a single DNA-binding α subunit plus multiple non-DNA-binding β subunits (including what became GABPB2) resolved the subunit composition of a key transcription factor for mitochondrial respiratory gene promoters.\",\n      \"evidence\": \"Protein purification from HeLa cells with peptide sequencing, EMSA, and promoter activity assays; parallel cDNA cloning with recombinant reconstitution\",\n      \"pmids\": [\"8383622\", \"8441384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of α–β interaction unknown at this stage\",\n        \"Functional differences between β subunit isoforms not addressed\",\n        \"Mechanism by which β subunits activate transcription unresolved\"\n      ]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrating that GABPB2 dimerizes through a C-terminal coiled-coil domain — capable of functionally replacing a leucine zipper — established the molecular basis for GABP heterotetramer assembly and showed that β1 and β2 can heterodimerize.\",\n      \"evidence\": \"Leucine zipper domain-swap functional assay, circular dichroism spectroscopy, co-immunoprecipitation\",\n      \"pmids\": [\"7958862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether β1/β2 heterodimerization versus homodimerization is preferred in vivo unknown\",\n        \"Physiological consequence of tetramerization on target gene selection not tested\"\n      ]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Mapping a conserved ~70-amino-acid transactivation domain within all four human NRF-2 β/γ subunits, and showing equal association with α and equal transcriptional potency, demonstrated that GABPB2 carries autonomous activation capacity indistinguishable from other isoforms in vitro.\",\n      \"evidence\": \"GAL4 fusion transactivation assays with deletion mapping, co-immunoprecipitation\",\n      \"pmids\": [\"7799916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Why multiple isoforms exist if activation potency is equivalent remained unexplained\",\n        \"In vivo isoform-specific promoter occupancy not examined\"\n      ]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Fine mutagenesis of the activation domain showed that tandem hydrophobic clusters — not glutamine residues — are the essential determinants of transactivation, refining the molecular requirements for NRF-2β function.\",\n      \"evidence\": \"Systematic alanine substitution mutagenesis with reporter assays in transfected cells\",\n      \"pmids\": [\"8816484\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of coactivators recruited by these hydrophobic motifs unknown at this point\"\n      ]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"The 2.15 Å crystal structure of the GABPα ETS domain–GABPβ ankyrin repeat heterodimer on DNA revealed the extensive protein–protein interface through which β subunits are recruited to α, establishing the structural framework for GABP complex assembly.\",\n      \"evidence\": \"X-ray crystallography at 2.15 Å resolution\",\n      \"pmids\": [\"9461436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structure captured β1 ankyrin repeats; whether GABPB2-specific insertions alter the interface was not resolved\",\n        \"No structure of the coiled-coil tetramerization domain\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of HCF-1 (C1) as a coactivator that directly contacts GABP and is required for GABP-dependent transcriptional activation linked the activation domain to a specific cofactor recruitment mechanism.\",\n      \"evidence\": \"Co-immunoprecipitation, mutagenesis correlated with loss of activation and HCF-1 binding\",\n      \"pmids\": [\"10675337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Experiment addressed GABP complex generically; isoform-specific interaction with GABPB2 not distinguished\",\n        \"Whether HCF-1 interaction is relevant beyond HSV IE gene context unclear\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that PRC, HCF-1, and NRF-2β form a trimeric complex on mitochondrial gene promoters — with HCF-1 bridging PRC to the NRF-2β activation domain — provided the mechanistic link between the coactivator cascade and mitochondrial respiratory chain gene expression.\",\n      \"evidence\": \"In vitro binding, co-immunoprecipitation, ChIP at TFB1M/TFB2M promoters, shRNA knockdown reducing cytochrome oxidase activity\",\n      \"pmids\": [\"18343819\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contribution of GABPB2 versus GABPB1 to PRC–HCF-1 complex at endogenous loci not dissected\",\n        \"Whether the trimeric complex operates at all NRF-2 targets or a subset is unknown\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genetic disruption in glioblastoma established that GABPB1L — not GABPB2 — is specifically required for TERT reactivation at mutant TERT promoters, demonstrating functional non-redundancy between the two paralogs in a disease-relevant context.\",\n      \"evidence\": \"CRISPR disruption, xenograft tumor models, telomere length analysis\",\n      \"pmids\": [\"30205050\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular basis of GABPB2's inability to substitute (e.g., expression level vs. intrinsic activity) not resolved\",\n        \"GABPB2 role defined negatively (cannot substitute) rather than by direct loss-of-function\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Forced overexpression of GABPB2 rescued GABPB1L-dependent proliferation and TERT expression in glioblastoma, showing that GABPB2 is intrinsically competent but limited by low endogenous expression — clarifying that expression level, not biochemical activity, underlies paralog non-redundancy.\",\n      \"evidence\": \"Inducible knockdown of GABPB1L with GABPB2 overexpression rescue, intracranial tumor models\",\n      \"pmids\": [\"33758097\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism regulating GABPB2 low expression not identified\",\n        \"Single-lab finding not yet independently confirmed\",\n        \"Whether GABPB2 upregulation occurs naturally as a resistance mechanism in tumors unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The physiological non-redundant functions of GABPB2 versus GABPB1 — beyond the TERT promoter context — remain undefined; no genome-wide target specificity, isoform-specific structural features, or regulatory mechanisms controlling GABPB2 expression have been characterized.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No ChIP-seq or CUT&RUN data distinguishing GABPB2-occupied versus GABPB1-occupied loci\",\n        \"No crystal structure of the GABPB2-specific C-terminal region or coiled-coil domain\",\n        \"Regulatory basis for low GABPB2 expression uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 4, 7]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 4, 7]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 7]}\n    ],\n    \"complexes\": [\n      \"GABP/NRF-2 heterotetramer\",\n      \"PRC–HCF-1–NRF-2β trimeric complex\"\n    ],\n    \"partners\": [\n      \"GABPA\",\n      \"GABPB1\",\n      \"HCFC1\",\n      \"PPRC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}